On August 24th, the signing and unveiling ceremony of the University of Macau- Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Chinese Medicine Innovation Joint Laboratory was held in the University of Macau. Ye Guilin, member of the Administrative Committee of Macao Science and Technology Development Fund, Ge Wei, Vice President of Macau University, Wang Yitao, Director of Macau Chinese Medicine R&D Center, Chen Xin, President of China Academy of Chinese Medicine, Li Peng, President of Tianjin Pharmaceutical Holdings Co., Ltd. and Chairman of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, and Xu Xiaoyang, Chief Strategy Officer of Tianjin Pharmaceutical Holdings Co., Ltd., attended the signing ceremony.

The University of Macau has outstanding scientific research level and technological innovation ability, ranking fifth in the world in terms of internationalization. It has the first national key laboratory in the field of traditional Chinese medicine and the first scientific and technological research and development platform in the Macao Special Administrative Region-the Macao Chinese Medicine Research and Development Center. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited of Tianjin Pharmaceutical Holdings Co., Ltd. is the cradle of modern preparation technology of traditional Chinese medicine, with 22 dosage forms, 599 drug approval numbers and 122 exclusive production varieties. Almost all innovative dosage forms of modern Chinese medicine come from Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited. It is known as the leader of innovative Chinese medicine. The University of Macau-Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Chinese Medicine Innovation Joint Laboratory is the first joint materialization laboratory for innovative research and development of Chinese medicine at home and abroad, which aims to anchor new frontier concepts, new technologies and new methods, deepen the connotation value of fine Chinese medicine, expand the new path of inheritance and innovation development of fine Chinese medicine driven by original innovation and led by scientific and technological innovation, and create a new research and development pattern combining innovative exploration research with applied research.

The General Secretary Xi Jinping attached great importance to the inheritance and innovation of traditional Chinese medicine and made a series of important instructions, pointing out the direction for the development of traditional Chinese medicine in the new era. The state has successively issued a series of planning schemes to support the R&D and industrialization of Chinese medicine in Guangdong-Hong Kong-Macao Greater Bay Area and build a highland for Chinese medicine construction, and Tianjin has also issued an action plan to strengthen the city with Chinese medicine, which puts forward the goal of building a Chinese medicine industrial cluster in an all-round way that matches the functional orientation of Tianjin's socialist modern metropolis and building a highland for Chinese medicine inheritance. The innovative development of Chinese medicine has ushered in a rare historical opportunity.

At the signing ceremony, President Zhang Mingrui said that inheritance is the source of innovation, and innovation is the vitality of inheritance. As a leader in innovative Chinese medicine, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited should take inheritance and innovation as its mission, and take the opportunity of the establishment of a joint laboratory to deepen its in-depth cooperation with the University of Macau in the field of Chinese medicine, compact scientific research to lead the innovation of Chinese medicine industry and dosage forms, lay the foundation for the development of excellent enterprises under the guidance of national health strategy, accumulate the development momentum of enterprises, and help enterprises take off twice.

In the future, the joint laboratory will focus on the innovative research and development of famous varieties of fine Chinese medicine, the improvement of traditional Chinese medicine dosage forms with the same name, and focus on the original innovation and exploration of traditional Chinese medicine, the expansion and innovation of large varieties of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, the construction of international joint platform and the cultivation of international innovative talents of traditional Chinese medicine, so as to actively give full play to the advantages of both sides and promote the inheritance and high-quality development of traditional Chinese medicine industry, thus boosting the development of Tianjin traditional Chinese medicine industry and its global expansion!